Fig. 7
From: PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Prediction of melanoma response to ICB immunotherapy by Overlap36. (a, b) Overlap36 and Overlap36sub multigene panels were analyzed for prediction of resistance to ICB in 25 cohorts treated with ICB. The details of individual cohorts are presented in Supplementary files. (c) Association of Overlap36sub component genes with T cell dysfunction value (top panel) and worst survival in cancer types treated with the indicated ICB (bottom panel). Ipi: Ipilumuman anti-CTLA4; Prog: progressed; PD1.Ipi_Prog and PD1.Ipi_Naive: treatment of melanoma by anti-PD1 on tumor progressed or naïve on Ipi. (d) Spearman correlation of GIMAP7 with PDL2, CD96, TIGIT, and BLTA in SKMC. (e) Reverse real-time PCR analysis of mouse Cimap7 gene expression in the indicated tumors (n = 3 tumors per tumor type). Cimap7 mRNA expressions in B16 Q152H, PCSK9, and D374Y tumors were presented at fold change to its expression in B16 EV tumors. (f) Prediction of resistance to ICB by Overlap36sub plus the 8-gene panel conserved between D374Y DEGs and IFNγ signature [98] in melanoma and other cancer types in 25 cohorts organized by TIDE [57]